Stryker has executed a definitive agreement to acquire Amplitude Vascular Systems, a developer of a next-generation intravascular lithotripsy platform for treating calcified peripheral arterial disease. The deal underscores Stryker’s strategy to bolster its Peripheral Vascular portfolio with advanced calcium-modification technology.

Amplitude Vascular’s IVL platform uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to uniformly fracture arterial calcium, improving luminal gain. The design emphasizes enhanced catheter deliverability, faster treatment speeds and increased therapy efficiency in complex vascular procedures.

Once regulatory clearances are secured, the IVL technology will complement Stryker’s existing portfolio of revascularization devices and support the company’s goal of expanding its presence in arterial disease treatment. The addition is expected to address unmet clinical needs and offer new treatment options to physicians.

The transaction remains subject to customary closing conditions, with both companies continuing independent operations until completion. Stryker and Amplitude Vascular plan to maintain business-as-usual activities during the integration period prior to finalizing the acquisition.